Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP102 Monotherapy in Advanced Solid Tumors
NCT07163325Phase 1Recruiting
- Sponsor
- EPICS Therapeutics
- Start
- Jul 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of EP102 in solid tumor (5 arms), sponsored by EPICS Therapeutics. Primary endpoints: Safety and tolerability of EP102 monotherapy at 21 days and Maximum Tolerated Dose at 21 days. Started Jul 2025; status: recruiting.
02
Drugs
EP102
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07163325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07163325.